First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Collaboration brings Staart Prime, ChilRun and NikoMom products to Yoginii’s platform, strengthening its family-focused wellness ecosystem and supporting women through motherhood and family care
The approval is supported by results from the Phase 3 SWOG 1826 trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
